EIF4A3 and hepatocellular carcinoma: Remarkably, the combination of siEIF4A3#1 and the FGFR4 inhibitor did not exerted more pronounced effects (Figure 7E), which further indicate that EIF4A3 may act in HCC cells through the control of FGF19/FGFR4 signalling.